Thu, May 15, 11:35 AM (60 days ago)
**Summary of Precision BioSciences, Inc. (DTIL) Q1 2025 Financial Health and Performance:** Precision BioSciences, Inc. (DTIL) reported a net loss of $20.6 million for Q1 2025, with an accumulated deficit of $503.0 million as of March 31, 2025. The company had $99.8 million in cash, cash equivalents, and restricted cash, with significant expenses in research and development ($13.6 million) and general and administrative costs ($8.6 million). Revenue for Q1 2025 was minimal, highlighting the company's focus on development rather than commercial sales. The company's cash runway is expected to support operations into the second half of 2026, with a focus on achieving first-in-human Phase 1 clinical data for two wholly-owned in vivo gene editing programs. DTIL faces uncertainties in regulatory approvals, market acceptance, and competition, with a strategic focus on leveraging the ARCUS genome editing platform for developing in vivo therapies for genetic and infectious diseases. The company's future financial performance will depend on successful development and commercialization of product candidates, strategic collaborations, and securing additional funding.